News & Events
 
The Drugs Technical Advisory Board has examined the issue of suspension of manufacture and sale of Pioglitazone on 19th July 2013 & has recommended that the Suspension of the drug should be revoked and allowed to be marketed subject to certain conditions the manufacturers shall mention on their package insert and promotional literature of the drug. Based on DTAB report Ministry of health & family welfare & Central Government revokes the notification G.S.R.379(E) dated 18th June 2013.
-------------------------------
A new study presented at EULAR 2013,the Annual Congress of the European League Against Rheumatism shows that one in eight patients at risk of developing a serious adverse drug event (ADE) is taking over the counter (OTC) non-steroidal anti-inflammatory drugs (NSAIDs), often to treat a musculoskeletal complaint Possible serious ADEs include gastrointestinal bleeding, peptic ulceration, high blood pressureand worsening heart failure.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.
-------------------------------
Researchers reported at the American Heart Association's 50th Annual Conference on Cardiovascular Disease Epidemiology and Prevention, that the increase in sugar consumption has led to more diabetes and heart disease over the past decade.

Testimonials
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
Slideshow Image 2
Slideshow Image 1
 
     
 
Glimepiride, Metformin Hydrochloride (SR) and Pioglitazone Tablets

 
  COMPOSITION:  
  GLIMIPRIDE + METFORMIN + PIOGLITAZONE  
     
  THERAPEUTIC INDICATIONS:  
  Glimitab MP Tablets are indicated once daily, as an adjunct to diet and exercise, to lower blood glucose. It is indicated as second-line therapy when diet, exercise, and the single agents or dual therapy do not result in adequate glycemic control in patients with type-2 diabetes.  
     
  DOSAGE AND ADMINISTRATION:  
 
Dosage should be individualized on the basis of both effectiveness and tolerability while not exceeding the maximum recommended daily dose [which is for glimepiride=8mg; pioglitazone=45mg; metformin sustained-release=2000 mg]. The combination should be given once daily with meals and should be started at a low dose. The initial recommended dose is one tablet of Glimitab MP once daily. Dosage should not exceed 3 tablets per day of Glimitab MP-1 or Glimitab MP-2
 
     
  CONTRAINDICATIONS :  
  Renal disease or renal dysfunction, as suggested by serum creatinine levels ≥1.5 mg/dL [males], ≥1.4 mg/dL [females] or abnormal creatinine clearance, which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia.
•Hepatic Impairment: clinical evidence of active liver disease or serum transaminase levels (ALT) ≥2.5 times the upper limit of normal.
•Congestive heart failure requiring pharmacologic treatment.
•Known hypersensitivity to this product or any of its components.
•Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. Diabetic ketoacidosis should be treated with insulin.
•Patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because the use of such products may result in acute alteration of renal function.
 
     
  WARNINGS & PRECAUTIONS:  
 
Congestive Heart Failure & other cardiac effects: Thiazolidinediones, including pioglitazone, which is a component of Glimitab MP, can cause fluid retention in some patients when used alone or in combination with < other antidiabetic agents, including insulin. Fluid retention may lead to or exacerbate heart failure.
 
     
  Back to Products  

 

 

         
 
 
Home | About Us | Products | Enquiry | Contact Us | Order | Carrer
     
  All Rights Reserved By : Cadell Health care Pvt Ltd. Designed & Maintained By : Daffodil Design & Prints